[Cyclosporine and idiopathic extramembranous glomerulopathy. Hypothesis, facts and questions in 1992].
The survey of open trials of Cyclosporin (CyA) in membranous nephropathy demonstrates that low dose CyA (4-5 mg/kg/day) given for a long term therapy (more than a year) can induce remission in 60-70% of the patients. Shorter therapy must be avoided because of the high rate of relapse after CyA withdrawal. Antiproteinuric effect of CyA does not seem to be related to an haemodynamic mechanism. Relapse of the nephrotic syndrome after CyA withdrawal after long term therapy can be observed but is far less frequent than in corticodependent nephrosis or in short term therapy with CyA. Further studies are needed to evaluate the risk of long-term nephrotoxicity and to determine what kind of patients should be treated. Controlled trials of CyA in membranous nephropathy against reference treatments are also warranted.
Rostoker
G
G
Service de Néphrologie, INSERM U 139, Hôpital Henri Mondor, Créteil, France.
D000818:Animals; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005921:Glomerulonephritis / Q000188:drug therapy*; D006801:Humans; D012074:Remission Induction
D016572:Cyclosporine
Ciclosporine et glomérulopathie extramembraneuse idiopathique. Hypothèses, faits et questions en 1992.